Raising High-Density Lipoprotein in Humans Through Inhibition of Cholesteryl Ester Transfer Protein: An Initial Multidose Study of Torcetrapib

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 24, Issue 3, 2004, Pages 490-497

  Clark, Ronald W ^a   Sutfin, Tamara A ^a   Ruggeri, Roger B ^a   Willauer, Ann T ^a   Sugarman, Eliot D ^a   Magnus Aryitey, George ^a   Cosgrove, Patricia G ^a   Sand, Thomas M ^a   Wester, Ronald T ^a   Williams, John A ^a   Perlman, Michael E ^a   Bamberger, Mark J ^a  

^a PFIZER INC   (United States)

Author keywords

Atherosclerosis; CETP; CP 529,414; HDL; Torcetrapib

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN E; CHOLESTEROL ESTER TRANSFER PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PROTEIN INHIBITOR; TORCETRAPIB; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; FEMALE; HUMAN; LIPOPROTEIN BLOOD LEVEL; MALE; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

ADOLESCENT; ADULT; APOLIPOPROTEINS; CARRIER PROTEINS; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ENZYME INHIBITORS; FEMALE; GLYCOPROTEINS; HUMANS; LIPIDS; LIPOPROTEINS; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; QUINOLINES;

EID: 12144287356     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000118278.21719.17     Document Type: Article

References (38)

1. Rhoads GG, Gulbrandsen CL, Kagan A. Serum lipoproteins and coronary heart disease in a population study of Hawaii Japanese men, N Engl J Med. 1976;294:293-298.
2. Gordon T, Castelli WP, Hjorland MC, Cannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med. 1977;62:707-714.
3. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD. High density lipoprotein cholesterol and cardiovascular disease. Four prospective Am studies. Circulation. 1989;79:8-15.
4. Manninen V, Tenkanen L, Koskinen P, Huttunen JK, Manttari M, Heinonen OP, Frick ML. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Circulation. 1992;85:37-45.
5. Gotto AM, Whitney E, Stein EA, Shapiro DR, Clearfield M, Weis S, Jou JY, Langendorfer A, Beere PA, Watson DJ, Downs JR, de Cani JS. Relationship between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study. Circulation. 2000;101:477-484.
6. Robbins SJ, Collins D, Wittes JT, Papademetriou V, Deedwania PC, Schaefer EJ, McNamara JR, Kashyap ML, Hershman JM, Wexler LF, Rubins HB. 2001. Relation of Gemfibrozil treatment and lipid levels with major coronary events. JAMA. 2001;285:1585-1591.
7. Barter P, Kastelein J, Nunn A, Hobbs R, Future Forum Editorial Board. 2003. High density lipoproteins (HDLs) and atherosclerosis; the unanswered questions. Atherosclerosis. 2003;168:195-211.
8. Bays HE, Dujovne CA, McGovern ME, White TE, Kashyap ML, Hutcheson AG, Crouse JR. Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin. Am J Cardiol. 2003;91:667-672.
9. Inazu A, Brown ML, Hesler CB, Agellon LB, Koizumi J, Takata K, Maruhama Y, Mabuchi H, Tall AR. Increased high density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N Engl J Med. 1990;323:1234-1238.
10. Barter PJ, Brewer HB, Chapman J, Hennekens CH, Rader DJ. Cholesteryl ester transfer protein: A novel target for raising HDL and inhibiting atherosclerosis. Arterioscl Thromb Vasc Biol. 2003;23:160-167.
11. Moriyama Y, Okamura T, Inazu A, Doi M, Iso H, Mouri Y, Ishikawa Y, Suzuki H, Iida M, Koizumi J, Mabuchi H, Komachi Y. A low prevalence of coronary heart disease among subjects with increased high-density lipoprotein cholesterol levels, including those with plasma cholesteryl ester transfer protein deficiency. Preventive Med. 1998;27:659-667.
12. Grooth J, Kuivenhoven J, Stalenhoef A, de Graaf J, Zwinderman A, Posma J, van Tol A, Kastelein J. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans. Circulation. 2002;105:2159-2165.
13. Clark RW, Moberly JB, Bamberger MJ. Low level quantification of cholesteryl ester transfer protein in plasma subfractions and cell culture media by monoclonal antibody-based immunoassay. J Lipid Res. 1995; 36:876-889.
14. Dias VC, Parsons HG, Boyd ND, Keane P. Dual-precipitation method for determination of high-density lipoprotein (HDL), HDL2, and HDL3 cholesterol concentrations. Clin Chem. 1988;34:2322-2327.
15. Pattnaik NM, Montes A, Hughes LB, Zilversmit DB. Cholesteryl ester exchange protein in human plasma: isolation and characterization. Biochim Biophys Acta. 1978;530:428-438.
16. Manual of Laboratory Operations, Lipid Research Clinics Program, I: Lipid and Lipoprotein Analysis. National Heart and Lung Institute, National Institutes of Health, Bethesda, MD; 1974.
17. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol without the use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
18. Brousseau ME, Schaefer EJ, Wolfe ML, Bloeden L, Digenio AG, Clark RW, Mancuso J, Rader DJ. Effects of a potent inhibitor of cholesteryl ester transfer protein on plasma lipoproteins in patients with low HDL cholesterol. N Engl J Med. (in press).
19. Duverger N, Rader D, Ikiwaki K, Nishiwaki M, Sakamoto T, Ishikawa T, Nagano M, Nakamura H, Brewer HB. Characterization of high-density apolipoprotein particles A-I and A-I:A-II isolated from humans with cholesteryl ester transfer protein deficiency. Eur J Biochem. 1995;227:123-129.
20. Ohta T, Nakamura R, Takata K, Saito Y, Yamashita S, Seikoh S, Matsuda I. Structural and functional differences of subspecies of apoA-I containing lipoprotein in patients with plasma cholesteryl ester transfer protein deficiency. J Lipid Res. 1995;36:696-704.
21. Koizumi J, Inazu I, Yagi K, Koizumi I, Uno Y, Kajinami K, Miyamoto S, Moulin P, Tall AR, Mabuchi H, Takeda R. Serum lipoprotein lipid concentration and composition in homozygous and heterozygous patients with cholesteryl ester transfer protein deficiency. Atherosclerosis. 1991; 90:189-196.
22. Chiba H, Akita H, Tsuchihashi K, Hui S, Takahashi Y, Fuda H, Suzuki H, Shubuya H, Tsuji M, Kobayashi K. Quantitative and compositional changes in high density lipoprotein subclasses in patients with various genotypes of cholesteryl ester transfer protein deficiency. J Lipid Res. 1997;38:1204-1216.
23. Yamashita S, Hui DY, Wetterau JR, Sprecher DL, Harmony JAK, Sakai N, Matsuzawa Y, Tarui S. Characterization of plasma lipoproteins in patients heterozygous for human plasma cholesteryl ester transfer protein (CETP) deficiency: plasma CETP regulates high density lipoprotein concentration and composition. Metabolism. 1991;40:756-763.
24. McPherson R, Lau P. Plasma kinetics of cholesteryl ester transfer protein in the rabbit. Effects of dietary cholesterol. Arterioscl Throm Vasc Biol. 1997;17:203-210.
25. Herbert P, Bernier D, Cullinane E, Edelstein L, Kantor M, Thompson P. High-density lipoprotein metabolism in runners and sedentary men. JAMA. 1984;252:1034-1037.
26. Daerr W, Pethke W, Windler E, Greten H. Biotinyl-high-density lipoproteins as a probe for the determination of high-density lipoprotein turnover in humans. Biochem Biophys Acta. 1990;1043:311-317.
27. Luo Y, Liang CP. The orphan nuclear receptor LRH-1 potentiates the sterol-mediated induction of the human CETP gene by liver X receptor. J Biol Chem. 2001;276:24767-24773.
28. Ishigami, M, Yamashita S, Sakai N, Arai T, Hirano K, Hiraoka H, Kameda-Takemura K, Matsuzawa Y. Large and cholesteryl ester-rich high-density lipoproteins in cholesteryl ester transfer protein (CETP) deficiency cannot protect macrophages from cholesterol accumulation induced by acetylated low-density lipoproteins. J Biochem. 1994;116:257-262.
29. Yamashita S, Maruyama T, Hirano K, Sakai N, Nakajima N, Matsuzawa Y. Molecular mechanisms, lipoprotein abnormalities and atherogenicity of hyperalphalipoproteinemia. Atherosclerosis. 2000;152:271-285.
30. Atger V, de la Llera Moya M, Bamberger M, Francone O, Cosgrove P, Tall A, Walsh A, Moatti N, Rothblat G. Cholesterol efflux potential of sera from mice expressing human cholesteryl ester transfer protein and/or human apolipoprotein AI. J Clin Invest. 1995;96:2613-2622.
31. Fournier N, Paul J, Atger V, Cogny A, Soni T, de la Llera Moya M, Rothblat G, Moatti N. HDL phospholipid content and composition as a major factor determining cholesterol efflux capacity from Fu5AH cells to human serum. Arterioscler Thromb Vasc Biol. 1997;17:2685-2691.
32. Fragoso Y, Skinner E. The role of subfractions of high density lipoprotein in the in vivo transport of cholesterol from cholesterol-loaded hepatic and peripheral endothelial cells in the New Zealand white rabbit. Comp Biochem & Physiol B: Comp Biochem. 1993;105:699-706.
33. Fragoso Y, Skinner E. Cholesterol-loading of peripheral tissues alters the interconversion of high density lipoprotein subfractions in rabbits. Int J Biochem. Cell Biol. 1996;28:151-163.
34. Zhong S, Sharp DS, Grove JS, Bruce C, Yano K, Curb JD, Tall AR. Increased coronary heart disease in Japanese-Am men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J Clin Invest. 1996;97:2917-2923.
35. Sugano M, Makino N, Sawada S, Otsuka S, Watanabe M, Okamoto H, Kamada M, Mizushima A. Effect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits. J Biol Chem. 1998;273:5033-5036.
36. Rittershaus C, Miller D, Thomas L, Picard M, Honan C, Emmett C, Pettey C, Adari H, Hammond R, Beattie D, Callow A, Marsh H, Ryan U. Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis. Arterioscler Thromb Vasc Biol. 2000;20:2106-2112.
37. Okamoto H, Yonemouri F, Wakitani K, Minowa T, Maeda K, Shinkai H. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature. 2000;406:203-207.
38. Huang Z, Inazu A, Nohara A, Higashikata T, Mabuchi H. Cholesteryl ester transfer protein inhibitor (JTT-705) and the development of atherosclerosis in rabbits with severe hypercholesterolaemia. Clin Sci. 2002; 103:587-594.